Fresh hope in advanced breast cancer...

LENTARON (4-hydroxyandrostenedione; 4-OHA) is a selective, fortnightly injectable aromatase inhibitor which marks an important development in the hormonal treatment of advanced breast cancer.

Up to now your main choice has been between anti-oestrogens and progostogens. Now LENTARON offers a highly selective way of stopping tumour growth by inhibiting oestrogen synthesis. 1

Quite simply, LENTARON prevents the aromatase enzyme from completing the final step in the conversion of androgen precursors to oestrogen.

With its unique and selective mode of action, LENTARON is not only effective in preventing disease progression, but it also has a prolonged duration of response and a low incidence of side-effects. 1

So for patients who have relapsed on tamoxifen, offer LENTARON and you'll offer renewed hope.

For a free LENTARON information pack, phone (0403) 272827 and ask for the Medical Information Department.